Antimycobacterial
Clofazimine
Adult dose
Dose: Leprosy MDT: 50mg OD + 300mg monthly supervised. MDR-TB: 100mg OD per WHO regimen
Route: PO
Frequency: OD
Clinical pearls
- Multibacillary leprosy and MDR-TB
- Take with food for absorption; warn patients about reversible skin discolouration
Contraindications
- Hypersensitivity
- Severe hepatic impairment
Side effects
- Reddish-brown skin pigmentation
- Dry skin
- GI upset
- QT prolongation
Interactions
- QT-prolonging drugs (esp. bedaquiline, moxifloxacin)
Monitoring
- LFTs
- ECG
Reference: BNF; WHO leprosy guidelines; https://bnf.nice.org.uk/drugs/clofazimine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023